What antibiotics to use to treat Pseudomonas (Pseudomonas aeruginosa)?

From the Guidelines

Pseudomonas aeruginosa infections should be treated with novel β-lactam agents such as ceftolozane/tazobactam or ceftazidime/avibactam as first-line options for targeted treatment, as recommended by recent guidelines 1. The treatment of Pseudomonas aeruginosa infections requires careful consideration of the antibiotic resistance pattern of the organism.

• The preferred treatment options include:
  • Ceftolozane/tazobactam 1.5-3 g IV every 8 hours
  • Ceftazidime/avibactam 2.5 g IV every 8 hours
  • Imipenem/cilastatin/relebactam 1.25 g IV every 6 hours
  • Colistin monotherapy or combination therapy
• Treatment duration generally ranges from 5-14 days depending on infection severity and site, as suggested by the guidelines 1.
• Susceptibility testing is crucial for guiding therapy, and local resistance patterns should also be considered when selecting treatment, as these can vary significantly between healthcare facilities.
• Combination therapy is often recommended for serious infections, typically pairing a beta-lactam with either an aminoglycoside or fluoroquinolone to prevent resistance development, as noted in the study 1. The most recent and highest quality study 1 provides strong recommendations for the treatment of Pseudomonas aeruginosa infections, with a certainty of evidence rated as moderate.
• The study recommends novel β-lactam agents such as ceftolozane/tazobactam and ceftazidime/avibactam as first-line options for targeted treatment.
• Other options, such as imipenem/cilastatin/relebactam and cefiderocol, may be considered as potential alternatives, as well as colistin-based therapy.

From the FDA Drug Label

Piperacillin and Tazobactam for Injection is indicated in adults and pediatric patients (2 months of age and older) for the treatment of nosocomial pneumonia (moderate to severe) caused by beta-lactamase producing isolates of Staphylococcus aureus and by piperacillin and tazobactam-susceptible Acinetobacter baumannii, Haemophilus influenzae, Klebsiella pneumoniae, and Pseudomonas aeruginosa (Nosocomial pneumonia caused by P. aeruginosa should be treated in combination with an aminoglycoside) Initial presumptive treatment of adult patients with nosocomial pneumonia should start with piperacillin and tazobactam for injection at a dosage of 4.5 grams every six hours plus an aminoglycoside, [totaling 18.0 grams (16.0 grams piperacillin and 2.0 grams tazobactam)], administered by intravenous infusion over 30 minutes.

The recommended antibiotics to treat Pseudomonas aeruginosa are:

• Piperacillin-tazobactam in combination with an aminoglycoside for nosocomial pneumonia 2 Note that levofloxacin may also be used to treat nosocomial pneumonia, but the provided text does not specify its use as a first-line treatment for Pseudomonas aeruginosa 3

From the Research

Antibiotic Treatment Options for Pseudomonas aeruginosa

• Ceftolozane-tazobactam is a potential treatment option, with a susceptibility rate of 96.5% against P. aeruginosa isolates 4
• Other effective antibiotics include colistin (99.4% susceptible), amikacin (98.1% susceptible) 4
• Combination therapy with an antipseudomonal β-lactam and an aminoglycoside or fluoroquinolone may be effective, but the choice of antibiotics should be guided by susceptibility testing 4, 5
• Monotherapies that exceeded 95% susceptibility include ceftolozane-tazobactam, amikacin, and colistin 4

Comparison of Antibiotic Regimens

• A study comparing ceftazidime, carbapenems, and piperacillin-tazobactam as single definitive therapy for P. aeruginosa bloodstream infection found no significant difference in mortality or clinical outcomes between the three regimens 6
• However, the study found that carbapenems were associated with a higher rate of resistant P. aeruginosa isolates 6
• A meta-analysis found that combination therapy with a β-lactam and an aminoglycoside or fluoroquinolone did not significantly reduce mortality compared to β-lactam monotherapy, but may be associated with a higher clinical cure rate 7

Emerging Resistance and Therapeutic Strategies

• The increasing prevalence of multidrug-resistant P. aeruginosa isolates poses a significant challenge to antibiotic therapy 8
• Novel agents, such as β-lactam/β-lactamase inhibitor combinations and cefiderocol, have shown promise in treating MDR-P. aeruginosa infections, but more comparative clinical data are needed 8
• Alternative therapies, such as bacteriophages, may also be effective in combating recurrent and refractory infections 8